Business News • PR NewsWire • Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016

Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016

Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016

PARIS, September 14, 2016 /PRNewswire/ -- Identification of Novel Molecular Mechanisms of Action of MD1003 in Neurodegeneration MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces that new preclinical data in adrenoleukodystrophy...

View More : http://www.prnewswire.com/news-releases/positive-preclinical-data-with-md1003-high-dose-pharmaceutical-grade-biotin-in-x...

Releted News by prnewswire

Jin Jiang International Hotels Successfully Held 2016 Japan Roadshow

Explore the Richness of the Naga Tradition With TUTC's Luxury Camps

2020 Animal Health Market Forecasts: Sanofi, Merck and Co., Eli Lilly and Company & Zoetis Inc. Reviewed

Sephora Adds Android App And New Pocket Hair Stylist Tool To Its Award-Winning Mobile Platforms

IoT Platform Market Outlook and Forecasts